Tumor Biology

, Volume 35, Issue 6, pp 5895–5904 | Cite as

CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects

Research Article

Abstract

Associations between CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk are inconclusive. To derive a more precise estimation of the association, we performed a meta-analysis by searching PubMed, EMBASE, Google scholar, and WanFang databases. A total of 20 eligible articles with 39 studies were included. Of those studies, there were 21 studies for CCR5-Delta32 polymorphism, 9 studies for CCR5-59029 polymorphism, and 9 studies for CCL5-403 polymorphism. Combined analysis revealed no associations between these polymorphisms and cancer risk. However, subgroup analysis by ethnicity suggested that CCR5-59029 polymorphism was associated with the risk of cancer among Asian populations (A vs. G: odds ratio (OR) = 1.36, 95 % confidence interval (CI) 1.13–1.65, P H = 0.27; AA vs. GG: OR = 2.07, 95 % CI 1.37–3.12, P H = 0.17; GA+AA vs. GG: OR = 1.35, 95 % CI 1.03–1.77, P H = 0.92; AA vs. GA+GG: OR = 1.98, 95 % CI 1.01–3.88, P H = 0.08), but not among Caucasian populations. CCL5-403 polymorphism was associated with the risk of cancer among African populations (A vs. G: OR = 0.68, 95 % CI 0.55–0.83, P H = 0.14; AA vs. GG: OR = 0.51, 95 % CI 0.33–0.77, P H = 0.52; AG vs. GG: OR = 0.58, 95 % CI 0.42–0.80, P H = 0.14; AG+AA vs. GG: OR = 0.56, 95 % CI 0.41–0.75, P H = 0.13), but not among Caucasian populations and Asian populations. Overall, this meta-analysis indicated that CCR5-Delta32 was not associated with the risk of cancer. CCR5-59029 polymorphism contributed to cancer risk among Asian populations, and CCL5-403 polymorphism was associated with the decreased risk of cancer among African populations.

Keywords

CCL5 CCR5 Polymorphism Cancer Meta-analysis 

Notes

Conflicts of interest

None

Supplementary material

13277_2014_1780_MOESM1_ESM.pdf (18 kb)
ESM 1 (PDF 17 kb)
13277_2014_1780_MOESM2_ESM.pdf (16 kb)
ESM 2 (PDF 16 kb)
13277_2014_1780_MOESM3_ESM.pdf (15 kb)
ESM 3 (PDF 15 kb)

References

  1. 1.
    Stewart TJ, Smyth MJ. Chemokine–chemokine receptors in cancer immunotherapy. Immunotherapy. 2009;1:109–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev. 2006;58:962–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39.CrossRefPubMedGoogle Scholar
  4. 4.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Weng CJ, Chien MH, Lin CW, Chung TT, Zavras AI, Tsai CM, et al. Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol. 2010;46:767–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsai HT, Yang SF, Chen DR, Chan SE. CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma. Med Oncol. 2012;29:2771–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Sáenz-López P, Carretero R, Cózar JM, Romero JM, Canton J, Vilchez JR, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer. 2008;8:382.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Liou JM, Lin JT, Huang SP, Wu CY, Wang HP, Lee YC, et al. RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol. 2008;43:115–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35:3362–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol. 2006;27:421–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity. 2009;31:711–21.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    van Deventer HW, O'Connor Jr W, Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 2005;65:3374–9.PubMedGoogle Scholar
  14. 14.
    Molon B, Gri G, Bettella M, Gómez-Moutón C, Lanzavecchia A, Martinez AC, et al. T cell costimulation by chemokine receptors. Nat Immunol. 2005;6:465–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity. 2009;30:616–25.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Kang SG, Piniecki RJ, Hogenesch H, Lim HW, Wiebke E, Braun SE, et al. Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine. Gastroenterology. 2007;132:966–81.CrossRefPubMedGoogle Scholar
  17. 17.
    Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746–55.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.CrossRefPubMedGoogle Scholar
  20. 20.
    Balistreri CR, Carruba G, Calabrò M, Campisi I, Di Carlo D, Lio D, et al. CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann N Y Acad Sci. 2009;1155:289–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 2012;31:1418–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Kucukgergin C, Isman FK, Dasdemir S, Cakmakoglu B, Sanli O, Gokkusu C, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 2012;511:7–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol. 2008;67:516–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Zambra FM, Biolchi V, Brum IS, Chies JA. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Hum Immunol. 2013;74:1003–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med. 2009;23:429–35.PubMedGoogle Scholar
  26. 26.
    Degerli N, Yilmaz E, Bardakci F. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem. 2005;38:248–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004;41:e59.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Vázquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology. 2009;74:414–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Bracci PM, Skibola CF, Conde L, Halperin E, Lightfoot T, Smith A, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma. 2010;51:497–506.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Gawron AJ, Fought AJ, Lissowska J, Ye W, Zhang X, Chow WH, et al. Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand J Gastroenterol. 2011;46:333–40.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res. 2008;14:45–50.CrossRefPubMedGoogle Scholar
  33. 33.
    Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res. 2008;17:87–91.PubMedGoogle Scholar
  34. 34.
    Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 2006;26:3669–74.PubMedGoogle Scholar
  35. 35.
    Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, et al. Chemokine ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African descent: a case–control study. Hered Cancer Clin Pract. 2012;10:16.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Clinical LaboratoryMedical College of Southeast UniversityNanjingChina
  2. 2.Key Laboratory of Developmental Genes and Human Disease, Ministry of EducationSoutheast UniversityNanjingChina
  3. 3.Department of Microbiology and ImmunologyMedical College of Southeast UniversityNanjingChina

Personalised recommendations